Which medications in the drug class Kallikrein Inhibitors are used in the treatment of Acquired Angioedema Due to C1 Inhibitor Deficiency?

Updated: May 20, 2020
  • Author: Amanda T Moon, MD; Chief Editor: William D James, MD  more...
  • Print

Kallikrein Inhibitors

These agents have specific kallikrein inhibitor activity, resulting in bradykinin reduction. They are useful for treating acute episodic attacks. The package insert carries a black box warning because a small subset of patients may have anaphylactic reactions to the drugs. They must be administered by medical personnel capable of treating anaphylaxis.

Ecallantide (Kalbitor)

A human plasma kallikrein inhibitor, ecallantide binds to plasma kallikrein and blocks its binding site. It reduces the conversion of kininogen to bradykinin. This agent is indicated for acute attacks of HAE. It is available as an injectable solution; 10 mg/mL per single-use vial.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!